Inflammation and cardiovascular disorders: more evidence to believe

Ping-Yen Liu, MD, PhD

Inflammation has been recognized as one of the initiators for the atherosclerotic plaque in vasculatures. Strong association has been observed among the progression of atherosclerosis especially rheumatic arthritis. Statin therapy, also ameliorate inflammatory response, can improve vasculature including improving endothelial function, smooth muscle proliferation and even retard the progression of arterial stiffness, thus protect from cerebrovascular outcomes.

Our Lab established several important inflammatory biomarkers, including phospholipase A2, matrix metalloproteinase-3 (stromelysin-1) in associated with cardiovascular disease, including acute myocardial infarction, acute coronary syndrome, metabolic syndrome, atherosclerosis, sarcopenic heart, peripheral occlusive artery disease. To prove our concept of hypothesis, we measured rho kinase activity, ROCK activity under statin treatment and support the evidence of pleiotropism of statin therapy on human beings.

More recently, several clinical trials using anti-inflammatory agents showed a promising effect by anti-inflammatory alone to improve cardiovascular outcome after myocardial infarction. However, how we adapt the new treatment strategy and whom we choose for more aggressive intervention remained an open question to date.